https://www.zacks.com/stock/news/2237009/3-stocks-to-buy-for-post-earnings-momentum?cid=CS-ZC-FT-video_blog-2237009
Mar 06, 2024 - The 2023 Q4 cycle has been primarily positive, underpinned by the Tech sector's strong contribution. And for those seeking post-earnings momentum, these three stocks have enjoyed precisely that.
zc:1192469427790685062
0
https://www.cnbc.com/2024/03/06/foot-locker-fl-earnings-q4-2023.html
Mar 06, 2024 - Foot Locker reported earnings as CEO Mary Dillon leads the legacy retailer through an ambitious turnaround. But some analysts say it has gone too slowly.
0
cnbc:2242893084978685559
0
https://www.zacks.com/stock/news/2236794/playags-ags-posts-breakeven-q4-earnings-tops-on-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236794
Mar 06, 2024 - PlayAGS' (AGS) fourth-quarter 2023 results reflect double-digit growth across all three operating segments.
zc:7141672431334278
0
https://www.zacks.com/stock/news/2236363/time-to-buy-into-target-s-tgt-post-earnings-rally?cid=CS-ZC-FT-stocks_in_the_news-2236363
Mar 05, 2024 - Target (TGT) headlined Tuesday's trading session with its stock spiking +12% after exceeding fourth quarter expectations this morning.
zc:8631245549792623438
0
https://www.zacks.com/stock/news/2236154/gitlab-gtlb-posts-gain-in-q4-beats-revenue-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2236154
Mar 05, 2024 - GitLab's (GTLB) fiscal fourth-quarter results benefit from solid subscription revenue growth driven by expanding clientele.
zc:-2774986087132023014
0
https://www.zacks.com/stock/news/2235960/victoria-s-secret-vsco-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2235960
Mar 05, 2024 - Victoria's Secret's (VSCO) fourth-quarter 2023 results are likely to benefit from high demand in China.
zc:422075082304556254
0
https://www.rttnews.com/story.aspx?Id=3429895
Mar 05, 2024 - Shares of CASI Pharmaceuticals, Inc. (CASI) were gaining more than 49 percent in pre-market activity on Nasdaq after the biopharmaceutical company announced Tuesday positive interim Phase 1 Data for BI-1206 (Anti-FcyRIIB antibody) in patients with relapsed/refractory or R/R indolent Non-Hodgkin's Lymphoma or iNHL.
0
rttnews:7072203401059335956
0
https://www.zacks.com/stock/news/2235402/playags-ags-gears-up-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2235402
Mar 04, 2024 - PlayAGS' (AGS) fourth-quarter 2023 results are likely to be aided by high contributions from all its operational segments. However, high costs might impact growth.
zc:-8493281687794795915
0
https://www.zacks.com/stock/news/2234580/is-post-holdings-post-a-great-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2234580
Mar 01, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zc:4365672205750334260
0
https://www.zacks.com/stock/news/2234525/hormel-foods-hrl-q1-earnings-sales-beat-estimates-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234525
Mar 01, 2024 - Hormel Foods' (HRL) first-quarter fiscal 2024 results reflect increased sales and earnings on the back of the solid Foodservice segment.
zc:-3473419737248233619
0